Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination

Vaccine

Volumn 29, Issue 20, 2011, Pages 3708-3713

  Parretta, Elisabetta ^a   Ianniello, Benedetta ^a   Ferrazin, Fernanda ^b   Rossi, Francesco ^a   Capuano, Annalisa ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Section of Pharmacovigilance   (Italy)

Author keywords

MF59 adjuvanted H1N1v vaccine; Vaccine safety profile

Indexed keywords

INFLUENZA VACCINE; MIFAMURTIDE;

ABORTION; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; ASTHENIA; BRAIN ISCHEMIA; CONGENITAL HEART MALFORMATION; CYANOSIS; CYTOMEGALOVIRUS INFECTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSARTHRIA; DYSPNEA; FATIGUE; FETUS DEATH; FEVER; HEART ARREST; HEMIPLEGIA; HUMAN; HYPERGLYCEMIA; HYPOTENSION; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; ITALY; KETOACIDOSIS; METABOLIC ACIDOSIS; MYALGIA; MYASTHENIA GRAVIS; MYOSITIS; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PANCYTOPENIA; PANDEMIC; PARESTHESIA; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRESYNCOPE; PRIORITY JOURNAL; PTOSIS; RESPIRATORY ARREST; RETINA EDEMA; RETINA HEMORRHAGE; SIDE EFFECT; SITUS INVERSUS; SKIN TINGLING; STRABISMUS; VEIN THROMBOSIS; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; ITALY; MALE; MIDDLE AGED; POLYSORBATES; PREGNANCY; PRODUCT SURVEILLANCE, POSTMARKETING; PUBLIC HEALTH; SQUALENE; VACCINATION; YOUNG ADULT;

EID: 79955101543     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.097     Document Type: Article

References (30)

1. European Medicine Agency (EMA). EU recommendation for the emergent novel H1N1 influenza vaccine composition. London, 4 June 2009 [online]. Available from URL: <>; [Accessed 22.07.2010]. http://www.emea.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500015392.pdf/.
2. Johansen K., Nicoll A., Ciancio B.C., Ktamarz P. Pandemic influenza A(H1N1) 2009 vaccines in the European Union. Euro Surveill 2009, 14(41):19361-19367.
3. European Medicine Agency (EMA). Authorisation procedures. [online]. Available from URL: <>; [Accessed 22.07.2010]. http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/special_topics/q_and_a/q_and_a_detail_000080.jsp%26murl=menus/special_topics/special_topics.jsp%26mid=WC0b01ac0580050100/.
4. European Medicine Agency (EMA). CHMP assessment report for Focetria. London, 24 September 2009 [online]. Available from URL: <>; [Accessed 22.07.2010]. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000710/WC500023755.pdf/.
5. Italian Ministry of Health. Misure urgenti in materia di protezione dal virus influenzale A(H1N1) (in Italian). 30 September2009 [online]. Available from URL: <>; [Accessed 02.10.2009]. http://www.normativasanitaria.it/jsp/dettaglio.jsp%3Faggiornamenti=%26attoCompleto=si%26id=30406%26page=%26anno=null/.
6. European Medicine Agency (EMA) European Strategy for Influenza A/H1N1. Vaccine Benefit-Risk Monitoring. October 2009 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/01/WC500044933.pdf.
7. Brown E.G., Wood L., Wood S The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999, 20(2):109-117.
8. European Medicine Agency (EMA). Summary of product characteristics. [online].Available from URL: <>; [Accessed 30.10.2010]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000710/WC500023749.pdf/.
9. Collet J.P., MacDonald N., Cashman N., Pless R. Monitoring signals for vaccine safety: the assessment of individual adverse event reports by an expert advisory committee. Advisory Committee on Causality Assessment. Bull World Health Organ 2000, 78(2):178-185.
10. Italian National Institute of Statistics ISTAT. Available from: http://demo.istat.it/.
11. Italian National Institute of Health (ISS) FluNews 3-9 May 2010 (in Italian). 2010 [online]. Available from URL: <>; [Accessed 30.06.2010]. http://www.epicentro.iss.it/focus/h1n1/pdf/flunews/FluNews_28.pdf/.
12. Cacciaguerra S., Gioviale M., Di Benedetto A. The importance of detailed diagnostic assessment in a case of partial situs inversus. Pediatr Surg Int 1998, 13(7):531-532.
13. Ellenberg S.S., Foulkes M.A., Midthun K., Goldenthal K.L. Evaluating the safety of new vaccines: summary of a workshop. Am J Public Health 2005, 95(5):800-807.
14. Griffin M.R., Braun M.M., Bart K.J. What should an ideal vaccine postlicensure safety system be?. Am J Public Health 2009, 99(2):345-350.
15. Swiss Agency for Therapeutic Product. Analysis of the PaniFlow® database on suspected adverse events following pandemic influenza (H1N1) 2009 vaccination in Switzerland. July 2010. Available from URL: http://www.swissmedic.ch/marktueberwachung/01315/index.html%3Flang=en.
16. Kraigher A., Učakar V. Surveillance of adverse events following immunization against pandemic influenza in Slovenia in season 2009/2010. Vaccine 2010, 28(33):5467-5472.
17. McMahon A.W., Iskander J., Haber P., Chang S., Woo E.J., Braun M.M., et al. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003. Pediatrics 2005, 115(2):453-460.
18. European Medicine Agency (EMA). Twentieth pandemic pharmacovigilance update. 8 April 2010 [online]. Available from URL: <>; [Accessed 20.07.2010]. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/06/WC500093182.pdf/.
19. European Medicine Agency (EMA). Twenty-first pandemic pharmacovigilance update 22 July. 2010 [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/07/WC500094857.pdf.
20. Agbabiaka T.B., Savović J., Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf 2008, 31(1):21-37.
21. Rosenberg M., Sparks R., McMahon A., Iskander J., Campbell J.D., Edwards K.M. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age. Vaccine 2009, 27(32):4278-4283.
22. Dodoo A.N., Renner L., van Grootheest A.C., Labadie J., Antwi-Agyei K.O., Hayibor S., et al. Safety monitoring of a new pentavalent vaccine in the expanded programme on immunisation in Ghana. Drug Saf 2007, 30(4):347-356.
23. Mak T.K., Mangtani P., Leese J., Watson J.M., Pfeifer D. Influenza vaccination in pregnancy: current evidence and selected national policies. Lancet Infect Dis 2008, 8(1):44-52.
24. Tamma P.D., Ault K.A., del Rio C., Steinhoff M.C., Halsey N.A., Omer S.B. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol 2009, 201(6):547-552.
25. Lim S.H., Lee J.H., Kim B.C., Jung S.U., Park Y.B., Lee C.S. Adverse reaction of influenza A (H1N1) 2009 virus vaccination in pregnant women and its effect on newborns. Vaccine 2010, 28(47):7455-7456.
26. Tsai T., Kyaw M.H., Novicki D., Nacci P., Rai S., Clemens R. Exposure to MF59-adjuvanted influenza vaccines during pregnancy-a retrospective analysis. Vaccine 2010, 28(7):1877-1880.
27. European Medicine Agency (EMA). Eleventh pandemic pharmacovigilance update. February 2010 .Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/02/WC500073992.pdf.
28. Maurer J., Uscher-Pines L., Harris K.M. Perceived seriousness of seasonal and A(H1N1) influenzas, attitudes toward vaccination, and vaccine uptake among U.S. adults: does the source of information matter?. Prev Med 2010, 51(2):185-187.
29. SteelFisher G.K, Blendon R.J., Bekheit M.M., Lubell K. The public's response to the 2009 H1N1 influenza pandemic. N Engl J Med 2010, 362(22):e65.
30. Vírseda S., Restrepo M.A., Arranz E., Magán-Tapia P., Fernández-Ruiz M., de la Cámara A.G., et al. Seasonal Pandemic A (H1N1) 2009 influenza vaccination coverage and attitudes among health-care workers in a Spanish University Hospital. Vaccine 2010, 28(30):4751-4757.